Search

Displaying results 8381 - 8390 of 10000 in total
  1. Drug

    Drozitumab

    go.drugbank.com/drugs/DB19106
    Investigational

    It was developed by Genentech as a drug for the treatment of cancers … Drozitumab is a human monoclonal antibody directed against tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), a member of tumor necrosis factor related apoptosis-inducing ligand (TRAIL)

  2. Drug

    NN344

    go.drugbank.com/drugs/DB05115
    Experimental

    The product is intended for basal insulin treatment of diabetes mellitus. … NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile.

  3. Drug

    Pemlimogene merolisbac

    go.drugbank.com/drugs/DB16286
    Investigational

    Pemlimogene merolisbac is under investigation in clinical trial NCT03371381 (An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab … Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung).

    Synonyms: (actan100), 5 tandem copies of a 21 amino acid fr, Recombinant live-attenuated double-deleted (ladd) strain of listeria monocytogenes (lm .delta.acta/.delta.inlb) expressing a fusion protein comprising the n-terminal 100 amino acids of the lm acta protein
  4. Drug

    SNS01-T

    go.drugbank.com/drugs/DB17302
    Investigational

    It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine. … SNS01-T is a gene therapy nanoparticle.

  5. Drug

    BMN-351

    go.drugbank.com/drugs/DB18186
    Investigational

    BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA. … It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD).

  6. Drug

    SR-9011

    go.drugbank.com/drugs/DB14014
    Experimental

    SR-9011 is a REV-ERB agonist. … SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues

  7. Drug

    GSK-945237

    go.drugbank.com/drugs/DB15345
    Investigational

    GSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose … and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.).

  8. Drug

    Ontamalimab

    go.drugbank.com/drugs/DB15298
    Investigational

    Ontamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)).

  9. Drug

    MaxAdFVIII

    go.drugbank.com/drugs/DB17713
    Experimental

    MaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.

  10. Drug

    Octacosanol

    go.drugbank.com/drugs/DB11220
    InvestigationalNutraceutical

    It has been studied as a potential therapeutic agent for the treatment of Parkinson's disease. … This high–molecular-weight organic compound is the main component of a natural product wax extracted from plants [A27245]. 1-octacosanol is reported to possess cholesterol-lowering effects, antiaggregatory